Spectral Med reported quarterly earnings above expectations, but its PMX regulatory review and financing remain central to the investment case.
Spectral Med Inc. (TSX: EDT) reported results before market open on November 6 for the quarter ended September 30, 2026. Earnings per share (EPS) were C$0.02, compared with analysts’ estimate of a C$0.01 loss. That’s a 300% positive surprise. The company has beaten estimates in three of the last four comparable quarters, but it remains unprofitable over the past 12 months. The supplied earnings data don’t include revenue or margin details.
Recent earnings trend
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$317.04M
52W high
$1.52
52W low
$0.86
1W change
+4.85%
Beta
0.19
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 191.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+191.7% Upside
Current Price
C$1.08
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
75.6%
Annualized
90-Day Vol
52.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.90
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.02 | C$0.78 – C$1.32 |
| 60 trading days | C$0.96 | C$0.66 – C$1.39 |
| 90 trading days | C$0.90 | C$0.58 – C$1.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-29 | — | -0.0100 | — |
| 2026-09-30 | 2026-11-06 | 0.0200 | -0.0100 | +300.0% |
| 2026-06-30 | 2026-08-07 | 0.0011 | -0.0100 | +111.0% |
| 2026-03-31 | 2026-05-08 | -0.0100 | -0.0100 | +0.0% |
| 2025-12-31 | 2026-03-26 | -0.0100 | -0.0200 | +50.0% |
| 2025-09-30 | 2025-11-07 | -0.1100 | -0.0100 | -1000.0% |
For Canadian investors, the key questions are how Spectral will respond to FDA requests for more PMX analyses, data and testing, and whether its recent financing can fund operations through the expected regulatory decision.
Investor takeaway: The EPS result is encouraging, but it beat a modest estimate from just one analyst. The available data don’t show a lasting earnings turnaround. The FDA is reviewing Spectral’s PMX application and has requested more information and testing. The company says its C$14-million convertible-note financing should fund operations through the expected FDA PMA decision. Investors should weigh that runway against potential dilution and regulatory risk.
C$0.02 quarterly EPS
Spectral reported EPS of C$0.02, compared with the C$0.01 loss analysts expected. That’s a 300% positive surprise. Since the estimate came from one analyst, the percentage should be viewed in light of the small consensus base.
Bull case
Spectral reported EPS of C$0.02 against an expected loss of C$0.01 and has beaten estimates in three of its last four reported quarters. The company says results from its Tigris Phase 3 trial support the PMX application, which the FDA formally accepted for review in June 2026.
Spectral also reported 12-month mortality of 52.8% among PMX-treated patients, compared with 66.7% for patients receiving standard care alone. These are company-reported results, not an independent assessment. The completed C$14-million convertible-note financing may fund operations through the expected FDA decision.
Bear case
Spectral’s earnings remain negative over the past 12 months, and the supplied snapshot shows a 0.00% profit margin. The FDA has requested additional analyses, data and testing, so the timing and outcome of its review remain uncertain. Convertible-note financing can also dilute shareholders.
At the last reported close, EDT.TO traded below its 50-day and 200-day moving averages. A statistical 90-day model also forecasts a lower mean price. Neither technical indicators nor model forecasts determine the company’s future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
